{"id":18096,"date":"2023-06-05T19:54:00","date_gmt":"2023-06-05T11:54:00","guid":{"rendered":"https:\/\/flcube.com\/?p=18096"},"modified":"2024-12-15T19:57:57","modified_gmt":"2024-12-15T11:57:57","slug":"neurophth-biotechnology-partners-with-sinopharm-group-to-commercialize-gene-therapy-nfs-01","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=18096","title":{"rendered":"Neurophth Biotechnology Partners with Sinopharm Group to Commercialize Gene Therapy NFS-01"},"content":{"rendered":"\n<p>China-based gene therapy specialist Neurophth Biotechnology Ltd has announced a strategic partnership with compatriot firm Sinopharm Group to jointly advance the marketing and commercialization of Neurophth&#8217;s NFS-01, an ophthalmic gene therapy targeting ND4 mutation in Leber&#8217;s Hereditary Optic Neuropathy (LHON) disease. Neurophth is aiming for NFS-01 to achieve a first-of-its-kind market approval in China, potentially as early as 2025. Additionally, Neurophth\u2019s NFS-02, which targets the ND1 mutation in LHON disease, is undergoing clinical studies in both China and the US.<\/p>\n\n\n\n<p><strong>Collaboration Focus and Scope<\/strong><br>Neurophth and Sinopharm will collaborate on a range of activities, including pre-market approval distribution and logistics management, post-market commercial storage and distribution, direct-to-patient (DTP) pharmacy services, and innovative payment solutions. This partnership leverages Sinopharm&#8217;s extensive network and experience in pharmaceutical distribution and marketing, complementing Neurophth&#8217;s expertise in gene therapy development.<\/p>\n\n\n\n<p><strong>Financial Details and Potential Impact<\/strong><br>While no financial details of the partnership have been disclosed, the collaboration is expected to significantly impact the accessibility and affordability of gene therapy treatments for LHON disease in China. The partnership aims to streamline the process from clinical trials to patient access, ensuring that innovative therapies like NFS-01 and NFS-02 can reach those in need.<a href=\"https:\/\/flcube.com\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based gene therapy specialist Neurophth Biotechnology Ltd has announced a strategic partnership with compatriot firm&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[66,1520,44],"class_list":["post-18096","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-gene-therapy","tag-neurophth-biotechnology","tag-ophthalmology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Neurophth Biotechnology Partners with Sinopharm Group to Commercialize Gene Therapy NFS-01 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based gene therapy specialist Neurophth Biotechnology Ltd has announced a strategic partnership with compatriot firm Sinopharm Group to jointly advance the marketing and commercialization of Neurophth&#039;s NFS-01, an ophthalmic gene therapy targeting ND4 mutation in Leber&#039;s Hereditary Optic Neuropathy (LHON) disease. Neurophth is aiming for NFS-01 to achieve a first-of-its-kind market approval in China, potentially as early as 2025. Additionally, Neurophth\u2019s NFS-02, which targets the ND1 mutation in LHON disease, is undergoing clinical studies in both China and the US.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=18096\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neurophth Biotechnology Partners with Sinopharm Group to Commercialize Gene Therapy NFS-01\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=18096\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-05T11:54:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-15T11:57:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18096#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18096\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Neurophth Biotechnology Partners with Sinopharm Group to Commercialize Gene Therapy NFS-01\",\"datePublished\":\"2023-06-05T11:54:00+00:00\",\"dateModified\":\"2024-12-15T11:57:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18096\"},\"wordCount\":214,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Gene therapy\",\"Neurophth Biotechnology\",\"Ophthalmology\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=18096#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18096\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=18096\",\"name\":\"Neurophth Biotechnology Partners with Sinopharm Group to Commercialize Gene Therapy NFS-01 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-06-05T11:54:00+00:00\",\"dateModified\":\"2024-12-15T11:57:57+00:00\",\"description\":\"China-based gene therapy specialist Neurophth Biotechnology Ltd has announced a strategic partnership with compatriot firm Sinopharm Group to jointly advance the marketing and commercialization of Neurophth's NFS-01, an ophthalmic gene therapy targeting ND4 mutation in Leber's Hereditary Optic Neuropathy (LHON) disease. Neurophth is aiming for NFS-01 to achieve a first-of-its-kind market approval in China, potentially as early as 2025. Additionally, Neurophth\u2019s NFS-02, which targets the ND1 mutation in LHON disease, is undergoing clinical studies in both China and the US.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18096#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=18096\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18096#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neurophth Biotechnology Partners with Sinopharm Group to Commercialize Gene Therapy NFS-01\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Neurophth Biotechnology Partners with Sinopharm Group to Commercialize Gene Therapy NFS-01 - Insight, China&#039;s Pharmaceutical Industry","description":"China-based gene therapy specialist Neurophth Biotechnology Ltd has announced a strategic partnership with compatriot firm Sinopharm Group to jointly advance the marketing and commercialization of Neurophth's NFS-01, an ophthalmic gene therapy targeting ND4 mutation in Leber's Hereditary Optic Neuropathy (LHON) disease. Neurophth is aiming for NFS-01 to achieve a first-of-its-kind market approval in China, potentially as early as 2025. Additionally, Neurophth\u2019s NFS-02, which targets the ND1 mutation in LHON disease, is undergoing clinical studies in both China and the US.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=18096","og_locale":"en_US","og_type":"article","og_title":"Neurophth Biotechnology Partners with Sinopharm Group to Commercialize Gene Therapy NFS-01","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=18096","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-06-05T11:54:00+00:00","article_modified_time":"2024-12-15T11:57:57+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=18096#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=18096"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Neurophth Biotechnology Partners with Sinopharm Group to Commercialize Gene Therapy NFS-01","datePublished":"2023-06-05T11:54:00+00:00","dateModified":"2024-12-15T11:57:57+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=18096"},"wordCount":214,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Gene therapy","Neurophth Biotechnology","Ophthalmology"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=18096#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=18096","url":"https:\/\/flcube.com\/?p=18096","name":"Neurophth Biotechnology Partners with Sinopharm Group to Commercialize Gene Therapy NFS-01 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-06-05T11:54:00+00:00","dateModified":"2024-12-15T11:57:57+00:00","description":"China-based gene therapy specialist Neurophth Biotechnology Ltd has announced a strategic partnership with compatriot firm Sinopharm Group to jointly advance the marketing and commercialization of Neurophth's NFS-01, an ophthalmic gene therapy targeting ND4 mutation in Leber's Hereditary Optic Neuropathy (LHON) disease. Neurophth is aiming for NFS-01 to achieve a first-of-its-kind market approval in China, potentially as early as 2025. Additionally, Neurophth\u2019s NFS-02, which targets the ND1 mutation in LHON disease, is undergoing clinical studies in both China and the US.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=18096#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=18096"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=18096#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Neurophth Biotechnology Partners with Sinopharm Group to Commercialize Gene Therapy NFS-01"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/18096","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=18096"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/18096\/revisions"}],"predecessor-version":[{"id":18098,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/18096\/revisions\/18098"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=18096"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=18096"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=18096"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}